MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
QURE

QURE

uniQure N.V.

$27.57
0.75
 (2.8%)
Exchange:  NASDAQ
Market Cap:  1.739B
Shares Outstanding:  17.595M
Delayed data
Calculate QURE Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Matthew Craig Kapusta
Full Time Employees:  209
Address: 
Paasheuvelweg 25a
Amsterdam
1105 BP
US
Website:  https://www.uniqure.com
uniQure N.V. operates as a specialized gene therapy company, dedicated to pioneering therapeutic solutions for individuals grappling with severe genetic and other debilitating illnesses. The firm’s most advanced project, Etranacogene dezaparvovec (designated as AMT-061), is currently progressing through a crucial Phase III pivotal trial, known as HOPE-B, targeting the treatment of hemophilia B. In addition to its flagship program, uniQure is actively developing several other candidates. This includes AMT-130, a gene therapy undergoing Phase I/II clinical assessment for Huntington’s disease, and AMT-060, also in Phase I/II clinical trials for hemophilia B. The company’s pipeline further extends to AMT-210 for Parkinson’s disease, AMT-260 aimed at temporal lobe epilepsy, and AMT-161, which addresses amyotrophic lateral sclerosis. Furthermore, AMT-240 is an early-stage, preclinical product candidate focused on autosomal dominant Alzheimer’s disease. Established in 1998, uniQure N.V. maintains its corporate headquarters in Amsterdam, Netherlands.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/09 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue15,84327,11916,098
Gross Profit2,2158,79214,412
EBITDA-253,100-160,745-116,587
Operating Income-282,871-184,294-187,827
Net Income-308,478-239,556-198,971

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets831,689556,536824,908
Total Liabilities624,019563,288626,007
Total Stockholders Equity207,670-6,752198,901
Total Debt138,40966,06163,393
Cash and Cash Equivalents241,360158,93080,240

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-145,929-182,728-177,963
Capital Expenditure-7,154-3,3680
Free Cash Flow-153,083-186,096-177,963
Net Income-308,478-239,556-198,971
Net Change in Cash13,371-84,2150

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)394,088.990Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)642,643.042Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)498,171Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-435,869.262Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-267,288.784Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-337,881.860Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)22,757.018Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)43,021.322Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)31,242.599Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)879,715.258Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,434,556.417Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,112,054.995Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.540Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.750Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.400Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)6Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
15.843M  ?P/S
 (TTM)
: 
92.2
?Net Income
 (TTM)
: 
-308478000  ?P/E
 (TTM)
: 
-7.95
?Enterprise Value
 (TTM)
: 
1.591B  ?EV/FCF
 (TTM)
: 
-9.25
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-1.46  ?ROIC
 (TTM)
: 
-0.26
?Net Debt
 (TTM)
: 
59.042M  ?Debt/Equity
 (TTM)
: 
0.42
?P/B
 (TTM)
: 
11.11  ?Current Ratio
 (TTM)
: 
10.4

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about QURE valuation

Is uniQure N.V. (QURE) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for uniQure N.V. (QURE) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is QURE a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether QURE trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is QURE’s P/E ratio?

You can see QURE’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for QURE?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is QURE a good long-term investment?

Whether QURE fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

QURE

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

2.8
MARKETSnap

Trading Metrics:

Open: 26.87   Previous Close: 26.82
Day Low: 26.8   Day High: 28.71
Year Low: 8.73   Year High: 71.5
Price Avg 50: 22.28   Price Avg 200: 27.05
Volume: 834975   Average Volume: 1.805M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
05-05-2026 09:26
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
06-04-2026 12:00
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
QURE CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
13-04-2026 12:58
QURE CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
11-02-2026 19:35
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
uniQure N.V. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V.
10-04-2026 15:43
uniQure N.V. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V.
QURE Deadline: Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
10-04-2026 13:15
QURE Deadline: Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read